GLP-1 Medications Guidelines Released for Women's Reproductive Years

Researchers at Marshall University have made a significant contribution to the global conversation surrounding the use of GLP-1 and incretin-based medications in pregnant women. As the demand for these medications continues to rise worldwide, particularly for the treatment of obesity, healthcare professionals are faced with the daunting task of navigating their safety and efficacy during pregnancy. This pressing concern has sparked an international effort to establish clear guidelines for the use of these medications in women before, during, and after pregnancy.

The Marshall University researchers, in collaboration with colleagues worldwide, have taken a crucial step in addressing this knowledge gap. Their study aims to shed light on the potential risks and benefits associated with GLP-1 and incretin-based medications in pregnant women, providing valuable insights for healthcare professionals to make informed decisions. The findings of this research have the potential to significantly impact the lives of millions of women worldwide, helping to ensure that they receive the best possible care during this critical period.

By contributing to this international effort, the researchers at Marshall University are helping to pave the way for the development of evidence-based guidelines for the use of GLP-1 and incretin-based medications in pregnant women. As the medical community continues to grapple with the complexities of these medications, this research serves as a vital step towards providing women with the care and support they need to navigate the challenges of pregnancy and beyond.